Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

NCT02742090 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

51

Enrollment

INDUSTRY

Sponsor class

Stopped (Strategic/Business Decision)

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Umbralisib

Sponsor

TG Therapeutics, Inc.